Evidence map›Paper›PMID 28117840›Full record

ArticleTranslational psychiatry2017

MiR-137-derived polygenic risk: effects on cognitive performance in patients with schizophrenia and controls.

D Cosgrove, D Harold, O Mothersill, R Anney, M J Hill, N J Bray, G Blokland, T Petryshen, Wellcome Trust Case Control Consortium, A Richards and 7 more

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. A comprehensive review of the genetic and biological evidence supports a role for MicroRNA-137 in the etiology of schizophrenia.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2018
    Review
  20. Association ofFrontiers in psychiatry · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 3 countries.

D CosgroveThe Cognitive Genetics & Cognitive Therapy Group, The School of Psychology and Discipline of Biochemistry, The Centre for Neuroimaging & Cognitive Genomics, National University of Ireland, Galway, Ireland.
D HaroldNeuropsychiatric Genetics Research Group, Department of Psychiatry, Institute of Molecular Medicine, Trinity College Dublin, Dublin, Ireland.
O MothersillThe Cognitive Genetics & Cognitive Therapy Group, The School of Psychology and Discipline of Biochemistry, The Centre for Neuroimaging & Cognitive Genomics, National University of Ireland, Galway, Ireland.
R AnneyNeuropsychiatric Genetics Research Group, Department of Psychiatry, Institute of Molecular Medicine, Trinity College Dublin, Dublin, Ireland.
M J HillInstitute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
N J BrayInstitute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
G BloklandPsychiatric and Neurodevelopmental Genetics Unit, Department of Psychiatry and Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA.
T PetryshenPsychiatric and Neurodevelopmental Genetics Unit, Department of Psychiatry and Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA.
Wellcome Trust Case Control Consortium
A RichardsMRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
K MantripragadaMRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
M OwenMRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
M C O'DonovanMRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
M GillNeuropsychiatric Genetics Research Group, Department of Psychiatry, Institute of Molecular Medicine, Trinity College Dublin, Dublin, Ireland.
A CorvinNeuropsychiatric Genetics Research Group, Department of Psychiatry, Institute of Molecular Medicine, Trinity College Dublin, Dublin, Ireland.
D W MorrisThe Cognitive Genetics & Cognitive Therapy Group, The School of Psychology and Discipline of Biochemistry, The Centre for Neuroimaging & Cognitive Genomics, National University of Ireland, Galway, Ireland.
G DonohoeThe Cognitive Genetics & Cognitive Therapy Group, The School of Psychology and Discipline of Biochemistry, The Centre for Neuroimaging & Cognitive Genomics, National University of Ireland, Galway, Ireland.
Cardiff University · GBTrinity College Dublin · IEOllscoil na Gaillimhe – University of Galway · IEBroad Institute · USCenter for Human Genetics · US

Funding

Genetic Determinants of Schizophrenia Intermediate PhenotypesR01MH092380 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI PETRYSHEN, TRACEY · 2012 to 2015
$2.4M
Medical Research Council G0802166Medical Research Council MR/L010305/1Medical Research Council MR/P005748/1NIMH NIH HHS R01 MH092380Wellcome Trust
6 · The paper itself

Abstract

Variants at microRNA-137 (MIR137), one of the most strongly associated schizophrenia risk loci identified to date, have been associated with poorer cognitive performance. As microRNA-137 is known to regulate the expression of ~1900 other genes, including several that are independently associated with schizophrenia, we tested whether this gene set was also associated with variation in cognitive performance. Our analysis was based on an empirically derived list of genes whose expression was altered by manipulation of MIR137 expression. This list was cross-referenced with genome-wide schizophrenia association data to construct individual polygenic scores. We then tested, in a sample of 808 patients and 192 controls, whether these risk scores were associated with altered performance on cognitive functions known to be affected in schizophrenia. A subgroup of healthy participants also underwent functional imaging during memory (n=108) and face processing tasks (n=83). Increased polygenic risk within the empirically derived miR-137 regulated gene score was associated with significantly lower performance on intelligence quotient, working memory and episodic memory. These effects were observed most clearly at a polygenic threshold of P=0.05, although significant results were observed at all three thresholds analyzed. This association was found independently for the gene set as a whole, excluding the schizophrenia-associated MIR137 SNP itself. Analysis of the spatial working memory fMRI task further suggested that increased risk score (thresholded at P=10

Indexed as

CognitionFacial RecognitionMemory, EpisodicMemory, Short-TermSchizophrenic PsychologyAdultBrainCase-Control StudiesFemaleFunctional NeuroimagingHumansMagnetic Resonance ImagingMaleMemoryMicroRNAsMiddle AgedMicroRNAsMIRN137 microRNA, human

Identifiers

PMID28117840
PMCPMC5545742
OpenAlexW2580377516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.